Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3Unknown 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43Specimen Handling 41pembrolizumab 40anlotinib 40sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 29Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 26lenvatinib 24apatinib 23Docetaxel 23Etoposide 22Biopsy 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × ARX788 × Clear all
NCT06224673 2026-05-01

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

University of California, San Francisco

Phase 2 Not yet recruiting
36 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06663748 2024-10-29

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Henan Cancer Hospital

Phase 2 Not yet recruiting
44 enrolled
Breast

Breast Neoplasms

NCT06578286 2024-08-29

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Fudan University

Phase 2 Not yet recruiting
44 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡